Inclusion Criteria:

          -  Histologically or cytologically confirmed immunotherapy naïve, metastatic or locally
             advanced non-small cell lung cancer not amenable to curative treatment. Subjects must
             have received one prior platinum based chemotherapy for non-small cell lung cancer
             and subjects with a documented activating mutation (EGFR, ALK or ROS) must also have
             received the appropriate therapy and progressed

          -  Histologically or cytologically confirmed unresectable or metastatic melanoma that
             had progressive disease during treatment with anti-PD-1/PD-L1 therapy. Subjects with
             BRAF activating mutation could have also received a BRAF inhibitor and/or MEK
             inhibitor regimen prior to anti-PD-1/PD-L1 therapy.

          -  Measurable disease by RECIST 1.1

          -  ECOG performance status of 0 or 1

          -  Adequate bone marrow, liver and kidney function

          -  Negative pregnancy test for women of child bearing potential

          -  Agreement to use effective methods of contraception per the protocol requirements

        Exclusion Criteria:

          -  Previous exposure to anti- CD40, CTLA-4, PD-1/PD-L1 or any other immunomodulatory
             agent (except PD-1/PD-L1 in subjects with metastatic melanoma)

          -  Second malignancy (solid or hematologic) within the past 5 years except locally
             curable cancers that have been apparently cured

          -  Active, known, clinically serious infections within the 14 days prior to first dose
             of investigational product

          -  Use of systemic corticosteroids or other systemic immunosuppressive drugs

          -  Active, known or suspected autoimmune disease

          -  History of (non-infectious) pneumonitis that required corticosteroids or current
             pneumonitis

          -  History of interstitial lung disease

          -  History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment for
             subjects with metastatic melanoma